 |
Rongrong Zhu, PhD
Associate Professor, School of Life Sciences and Technology, Tongji University |
Dr. Zhu received her BS in Environmental Engineering and PhD in Biomedical Engineering from Tongji University, China. During her postdoctoral study at Dr. Rigas’ lab, she investigated a drug delivery system for the treatment of non-small cell lung cancer. As part of our group from 2009-2010, Dr. Zhu worked on the metabolism and pharmacokinetics of novel anti-cancer agents in nano-carrier formulation in our lab.
Dr. Zhu is currently collaborating with us on drug development.
Selected Publications
- Zhu R, Cheng KW, Mackenzie G, Huang L, Sun Y, Xie G, Vrankova K, Constantinides PP, Rigas B. Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles. Pharm Res. 2012 Nov;29(11):3090-101. doi: 10.1007/s11095-012-0801-x. Epub 2012 Jun 22. PubMed PMID: 22723123; PubMed Central PMCID: PMC3584452.
- Zhu Y, Wu Y, Zhang H, Wang Z, Wang S, Qian Y, Zhu R. Enhanced Anti-Metastatic Activity of Etoposide Using Layered Double Hydroxide Nano Particles. J Biomed Nanotechnol. 2015 Dec;11(12):2158-68. PubMed PMID: 26510310.
- Wu Y, Zhu R, Ge X, Sun X, Wang Z, Wang W, Wang M, Liu H, Wang S. Size-dependent effects of layered double hydroxide nanoparticles on cellular functions of mouse embryonic stem cells. Nanomedicine (Lond). 2015 Dec;10(23):3469-82. doi: 10.2217/nnm.15.158. Epub 2015 Nov 26. PubMed PMID: 26607261.
- Zhu R, Wang Q, Zhu Y, Wang Z, Zhang H, Wu B, Wu X, Wang S. pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer. Acta Biomater. 2016 Jan 1;29:320-32. doi: 10.1016/j.actbio.2015.10.029. Epub 2015 Oct 17. PubMed PMID: 26485164.
For a complete list of publications, Click Here.
